• Earlier this month, Progyny, Inc. launched Progyny Select, a fully insured supplemental fertility and family-building plan designed to give small U.S. employers access to comprehensive, fixed-premium fertility and women’s health coverage through brokers, health plans, and general agents for the 2027 plan year.
• The plan packages Progyny’s managed provider network, Smart Cycle benefit design, and concierge care advocates into a pooled-risk model that aims to lower financial and structural barriers to fertility and women’s health support across adoption, surrogacy, pregnancy, postpartum, parenting, and menopause.
• We’ll now examine how Progyny Select’s fixed-cost supplemental coverage for small employers may influence Progyny’s existing investment narrative.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Progyny Investment Narrative Recap

To own Progyny, you have to believe employer demand for fertility and broader women’s health benefits will remain strong enough to justify its specialized, outcomes-focused model. The launch of Progyny Select opens a new lane with small employers, but its impact on the near term still hinges on how quickly brokers and health plans adopt it. The biggest risk remains employer cost-cutting or benefit reprioritization, which could offset gains from new offerings like this.

Among recent developments, Progyny’s sizable share repurchase program stands out next to Progyny Select. Since November 2025, the company has bought back about US$159.4 million of stock, equal to 7.57% of shares outstanding. For investors, pairing this capital return with a new fully insured product for small employers highlights two key parts of the current story: management’s confidence in the business and an effort to broaden the client base beyond large, high-utilization industries.

But while Progyny Select widens access, investors should also weigh how employer cost controls could still limit benefit adoption and...

Progyny's narrative projects $1.6 billion revenue and $112.9 million earnings by 2028.

Uncover how Progyny's forecasts yield a $30.91 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming only about US$1.5 billion in revenue and US$88 million in earnings by 2028, and when you compare that to concerns about policy shifts shrinking Progyny’s eligible customer base, it shows just how much views can differ and why it is worth considering several perspectives before deciding what this new small employer product might really mean.

Explore 4 other fair value estimates on Progyny - why the stock might be worth just $26.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Progyny research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Progyny research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Progyny's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.